Fred Cohen - BioCryst Pharmaceuticals Director
| BCRX Stock | USD 4.16 0.05 1.19% |
Director
Dr. Fred E. Cohen, M.D., Ph.D., serves as a Director of BioCryst Pharmaceuticals, Inc. In 2001, Dr. Cohen joined TPG Capital, a private investment firm, to initiate and lead TPGs venture efforts in biotechnology and life sciences. He retired from this role at the end of 2016 and now serves as a Senior Advisor to TPG. Beginning in 1986, and until his retirement in 2016, Dr. Cohen served as a member of the faculty of University of California, San Francisco . At UCSF, Dr. Cohen served as an Internist for hospitalized patients, a consulting Endocrinologist and as the Chief of the Division of Endocrinology and Metabolism. His research interests include structure based drug design, prion diseases, computational biology and heteropolymer chemistry. Dr. Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, his M.D. from Stanford and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. He is a Fellow of the American College of Physicians and the American College of Medical Informatics and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen was elected to the National Academy of Medicine of the National Academy of Sciences in 2004 and the American Academy of Arts and Sciences in 2008. Currently, Dr. Cohen also serves on the Board of Directors of Genomic Health, Inc., Veracyte, Inc., Tandem Diabetes Care, Inc., Five Prime Therapeutics, Inc., UroGen Pharma Ltd., and CareDx, Inc., as well as on the Boards of several privately held companies. Dr. Cohens extensive expertise in the pharmaceutical industry, private investment expertise and experience serving on boards of biotechnology companies contribute valuable insight and experience to the Board. since 2013.
| Age | 60 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 919 859 1302 |
| Web | https://www.biocryst.com |
BioCryst Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1157) % which means that it has lost $0.1157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.2537) %, meaning that it created substantial loss on money invested by shareholders. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Julian Adams | Pieris Pharmaceuticals | 62 | |
| Bernd Metzner | Anavex Life Sciences | 47 | |
| Patrick Scannon | Cassava Sciences | 69 | |
| Matthew Foehr | Viking Therapeutics | 45 | |
| Kurt Graves | Seres Therapeutics | 50 | |
| James Daly | Madrigal Pharmaceuticals | N/A | |
| Christina Takke | Pieris Pharmaceuticals | 44 | |
| Beth Seidenberg | Atara Biotherapeutics | 61 | |
| Peter Hutt | Seres Therapeutics | 80 | |
| Frederick Craves | Madrigal Pharmaceuticals | 72 | |
| David Milligan | Madrigal Pharmaceuticals | 77 | |
| Eric Dobmeier | Atara Biotherapeutics | 48 | |
| Stephen Knight | Blueprint Medicines Corp | 55 | |
| Rene Russo | X4 Pharmaceuticals | 42 | |
| Steven Prelack | Pieris Pharmaceuticals | 56 | |
| Graham Cooper | Kezar Life Sciences | 48 | |
| Donald Kufe | Madrigal Pharmaceuticals | 69 | |
| Mark Coleman | Axsome Therapeutics | 49 | |
| Michael Kauffman | Kezar Life Sciences | 54 | |
| Matthew Singleton | Viking Therapeutics | 65 | |
| Charles Rowland | Viking Therapeutics | 59 | |
Management Performance
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.12 |
BioCryst Pharmaceuticals Leadership Team
Elected by the shareholders, the BioCryst Pharmaceuticals' board of directors comprises two types of representatives: BioCryst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioCryst. The board's role is to monitor BioCryst Pharmaceuticals' management team and ensure that shareholders' interests are well served. BioCryst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioCryst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rob Bennett, Vice President Investor Relations & Operations | ||
| Alane Barnes, VP, General Counsel and Corporate Secretary | ||
| Elliott Berger, VP Affairs | ||
| Stanley Erck, Independent Director | ||
| Robert Ingram, Director | ||
| William MBBS, Chief Officer | ||
| Stephanie Angelini, Chief Officer | ||
| Charles Sanders, Independent Director | ||
| Jon Stonehouse, CEO and President and Executive Director | ||
| Charles Gayer, Senior Officer | ||
| Kenneth Lee, Independent Director | ||
| Stephen Aselage, Director | ||
| William Sheridan, Senior Vice President Chief Medical Officer | ||
| Nancy Hutson, Independent Director | ||
| Yarlagadda Babu, Sr. VP of Drug Discovery | ||
| Fred Cohen, Director | ||
| George Abercrombie, Non-Executive Independent Chairman of the Board | ||
| Thomas Staab, CFO, Senior Vice President Principal Accounting Officer, Treasurer | ||
| Michael Jones, Executive Officer | ||
| Lynne Powell, Senior Vice President Chief Commercial Officer | ||
| John Bluth, IR Contact Officer | ||
| Megan Sniecinski, Chief Business Officer | ||
| Sanj Patel, Director | ||
| Theresa Heggie, Director | ||
| Anthony Doyle, Senior CFO | ||
| MD FAAP, Chief Officer |
BioCryst Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioCryst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.68) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 1.32 B | ||||
| Shares Outstanding | 206.15 M | ||||
| Shares Owned By Insiders | 1.22 % | ||||
| Shares Owned By Institutions | 88.07 % | ||||
| Number Of Shares Shorted | 34.39 M | ||||
| Price To Earning | (7.11) X |
Pair Trading with BioCryst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against BioCryst Stock
| 0.7 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
| 0.69 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.6 | ELYM | Eliem Therapeutics Upward Rally | PairCorr |
| 0.46 | KRYS | Krystal Biotech Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.